Qureight: Turning Traction into Credibility with Pharma and Biotech

Qureight is an AI-driven clinical data curation company that analyses complex medical images and data, with a particular focus on deep lung diseases such as pulmonary fibrosis. The company came to SomX to win media coverage for a run of upcoming partnerships and to raise its profile ahead of a planned fundraise, targeting audiences across life sciences, pharma and biotech. Qureight had compelling science, partnerships with major players and strong commercial traction, but its profile did not yet reflect it. With several announcements in the pipeline, it needed more pace and polish in its PR and strategic communications, alongside an updated investor deck and web presence. As new internal stakeholders came on board, aligning quickly on messaging mattered just as much.
Client
Qureight
Category
Public Relations, Marketing, Design
Services
Media Relations, Thought Leadership, Social Content, Graphic Design, Animation
Qureight: Turning Traction into Credibility with Pharma and Biotech

Solution

We built and delivered a multi-channel communications plan to showcase Qureight's momentum, credibility and market opportunity.

A strategic PR cadence

We mapped coverage to Qureight's key milestones, keeping momentum through partnership announcements, Q&As and feature stories.

Targeted storytelling

We shaped narratives that drew out Qureight's differentiators in AI and drug development, and raised the visibility of its founder and leadership.

Integrated delivery

PR, content, design and strategy worked together so the message stayed consistent across earned and owned channels.

Design and collateral refresh

We delivered a full visual redesign of Qureight's Q3 2025 investor deck and template, aligning the look and feel with the company's growth, and updated web and comms materials for consistency.

Stakeholder alignment

We built strong relationships with new internal leads, with regular reporting and senior strategic input through a high-velocity news cycle.

Results

  • 37+ pieces of earned coverage in six months: more than twelve times the contracted volume between January and June 2025, reaching an audience of around 4.72M unique visitors a month.
  • Partnership announcements amplified: high-impact coverage of the Avalyn Pharma, RemedyCell, Rein and Vicore partnerships across Drug Discovery World, FirstWord Pharma, BioPharma APAC, Pharmaphorum, Drug Target Review, Journal of Clinical Studies and Manufacturing Chemist.
  • Positioned as a category leader: thought leadership across Drug Discovery World, Pharmaphorum, Drug Target Review and Journal of Clinical Studies.
  • A raised founder and leadership profile: Q&As in Drug Discovery World and Pharmafocus, a company profile in Startups Magazine, and a panel appearance at Google's Future of Life Sciences Tech Forum.
  • Direct investor interest: inbound approaches from investors linked to the coverage, ahead of the planned raise.

Reflection

Qureight had the science and the partnerships, but its public profile lagged well behind the work. Over a fast-moving six months we ran a PR and content programme that kept pace with a dense announcement schedule, held quality across every placement, and made the company legible to pharma, biotech and investors at once. The design and deck refresh gave that story a consistent frame. By the time Qureight moved towards its raise, its profile finally matched its traction.

Other Projects

Healthtech Pigeon
Pfizer
MORE WORK